No Data
A Post-Mortem on Cassava Sciences
Unpacking the Latest Options Trading Trends in Cassava Sciences
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
What's Left in Cassava After Phase 3 Setback for Alzheimer's Drug
Express News | Cassava Sciences Shares Fall 4% After 84% Slump in Previous Session
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)